Gilead Prices $2 Billion of Senior Unsecured Notes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Gilead Sciences (GILD) shares oversold argues BofA
September 8, 2023 8:54 AM EDTBofA analyst Geoff Meacham upgraded shares of Gilead Sciences (NASDAQ: GILD) to Buy from Neutral, with a price target of $95, up from $88 per share, in a note to clients on Friday.
The analyst told investors that the pharmaceutical company's HIV drug upside remains... More
